Designing modulators of dimethylarginine dimethylaminohydrolase (DDAH): a focus on selectivity over arginase.

Juerke Kotthaus, Dennis Schade, Joscha Kotthaus, Bernd Clement

Pharmaceutical and Medicinal Chemistry, Christian-Albrechts-University, Gutenbergstr. 76-78, Kiel, Germany.

Journal of enzyme inhibition and medicinal chemistry 2012 Feb

filter terms:

DDAH inhibition presents a novel promising pharmaceutical strategy to lower NO formation. To date, several potent DDAH inhibitors have been published, most of them representing analogues of l-arginine. While inhibitory effects on NOSs have already been considered, selectivity over arginase has been neglected so far. In our view, the latter selectivity is more important since an additional inhibition of arginase decreases the desired effects on NO levels. Thus, we particularly focus on selectivity over arginase. We present a comprehensive selectivity profile of known DDAH inhibitors by covering their inhibitory potency on arginase. Among the studied compounds, N(ω)-(2-methoxyethyl)-l-arginine (2a, L-257) that is already selective over NOSs also only modestly affected arginase activity and is thus far the most suitable DDAH inhibitor for pharmacological studies.

Citation

Juerke Kotthaus, Dennis Schade, Joscha Kotthaus, Bernd Clement. Designing modulators of dimethylarginine dimethylaminohydrolase (DDAH): a focus on selectivity over arginase. Journal of enzyme inhibition and medicinal chemistry. 2012 Feb;27(1):24-8